Deal volumes for global pharmaceutical mergers and acquisitions were lower in 2023 than they were 10 years ago. They’ve also been lower, on average, than the four years prior to the highs in 2018 and 2019.
There were some encouraging signs as the industry (and especially large drugmakers) headed into 2024, including a rise in average premiums in the pharma industry, yet 2024’s numbers year to date point to a down year for these types of deals.
Little Rebound for Pharma M&A Deal Volumes
Global M&A deal volumes for the pharmaceutical industry group over the past decade peaked in ...